Her2+ Breast Cancer Therapeutics
1. Nerlynx patent expiration
Treatment: Use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the me...
NERLYNX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6288082 | PUMA BIOTECH | Substituted 3-cyanoquinolines |
Sep, 2019
(6 years ago) | |
| US7399865 | PUMA BIOTECH | Protein tyrosine kinase enzyme inhibitors |
Dec, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8790708 | PUMA BIOTECH | Coated tablet formulations and uses thereof |
Nov, 2030
(4 years from now) | |
| US9211291 | PUMA BIOTECH | Treatment regimen utilizing neratinib for breast cancer |
Mar, 2030
(4 years from now) | |
| US9265784 | PUMA BIOTECH | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
Aug, 2029
(3 years from now) | |
| US8669273 | PUMA BIOTECH | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
Jul, 2031
(5 years from now) | |
| US8518446 | PUMA BIOTECH | Coated tablet formulations and uses thereof |
Nov, 2030
(4 years from now) | |
| US9630946 | PUMA BIOTECH | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
Oct, 2028
(2 years from now) | |
| US9139558 | PUMA BIOTECH | Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
Oct, 2028
(2 years from now) | |
| US7982043 | PUMA BIOTECH | Protein tyrosine kinase enzyme inhibitors |
Oct, 2025
(3 months ago) | |
| US10035788 | PUMA BIOTECH | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
Oct, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 17, 2022 |
| New Indication(I-823) | Feb 25, 2023 |
| New Dosing Schedule(D-182) | Jun 28, 2024 |
Drugs and Companies using NERATINIB MALEATE ingredient
NCE-1 date: 17 July, 2021
Market Authorisation Date: 17 July, 2017
Dosage: TABLET
How can I launch a generic of NERLYNX before it's drug patent expiration?
More Information on Dosage
NERLYNX family patents
2. Tryptyr patent expiration
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11850221 | ALCON LABS INC | Ophthalmic pharmaceutical compositions and uses thereof |
Dec, 2042
(16 years from now) | |
| US10028920 | ALCON LABS INC | Methods for treating occular irritation involving tearing by administering modulators of TRPM8 |
Sep, 2031
(5 years from now) | |
| US9433679 | ALCON LABS INC | Use of TRMP8 for treating opthalmic diseases or conditions involving tearing |
Sep, 2031
(5 years from now) | |
| US9095609 | ALCON LABS INC | Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia |
Sep, 2031
(5 years from now) | |
| US12336971 | ALCON LABS INC | NA |
Dec, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2030 |
Drugs and Companies using ACOLTREMON ingredient
NCE-1 date: 28 May, 2029
Market Authorisation Date: 28 May, 2025
Dosage: SOLUTION/DROPS
More Information on Dosage
TRYPTYR family patents
3. Tukysa patent
expiration
Treatment: Combination treatment with tucatinib and trastuzumab of adults with ras wild-type her2-positive unresectable or metastatic colorectal cancer that has progressed following previous treatment as claimed...
TUKYSA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7452895 | SEAGEN | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Nov, 2025
(a month ago) | |
| US8648087 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
Apr, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11666572 | SEAGEN | Treatment of HER2 positive cancers |
Apr, 2038
(12 years from now) | |
| US11504370 | SEAGEN | Treatment of brain cancer |
Mar, 2033
(7 years from now) | |
| US12048698 | SEAGEN | Treatment of HER2 positive cancers |
Apr, 2038
(12 years from now) | |
| US9457093 | SEAGEN | Solid dispersions of a ERB2 (HER2) inhibitor |
Oct, 2032
(6 years from now) | |
| US9693989 | SEAGEN | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
May, 2027
(1 year, 3 months from now) | |
| US11207324 | SEAGEN | Treatment of HER2 positive cancers |
Apr, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-906) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-309) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-422) | Jan 19, 2030 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Dosage: TABLET
More Information on Dosage
TUKYSA family patents
4. Tykerb patent expiration
Treatment: Treatment of patients with advanced or metastatic breast cancer whose tumors overexpress her2 and who have received prior therapy including anthracycline, a taxane and trastuzumab
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8513262 | NOVARTIS | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan, 2019
(7 years ago) | |
| US8821927 | NOVARTIS | Pharmaceutical composition |
Sep, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6727256 | NOVARTIS | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
Jan, 2019
(7 years ago) | |
| US6713485 | NOVARTIS | Heterocyclic compounds |
Sep, 2020
(5 years ago) | |
| US6391874 | NOVARTIS | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
Jul, 2017
(8 years ago) | |
| US7157466 | NOVARTIS | Quinazoline ditosylate salt compounds |
Nov, 2021
(4 years ago) | |
| US6828320 | NOVARTIS | Heterocyclic compounds |
Jul, 2017
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2012 |
| New Indication(I-620) | Jan 29, 2013 |
| M(M-235) | Dec 06, 2021 |
Drugs and Companies using LAPATINIB DITOSYLATE ingredient
NCE-1 date: 14 March, 2011
Market Authorisation Date: 13 March, 2007
Dosage: TABLET
How can I launch a generic of TYKERB before it's drug patent expiration?
More Information on Dosage
TYKERB family patents